Dynavax Technologies Corporation
Records under this name other than the patents Dynavax Technologies Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 28 patents it holds.
Back to Dynavax Technologies Corporation
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,918,648 | Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,751,412 | Combination of a PD-1 Antagonist and Cpg-C Type Oligonucleotide for Treating Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,759,305 | Methods and compositions for inhibition of innate immune responses and autoimmunity Lapsed on the fee record Ended Jun 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Jun 24, 2026 | From the USPTO record |
| US 7,745,606 | Immunostimulatory sequence oligonucleotides and methods of using the same Term ended Term ended May 2, 2025 · From the USPTO record | Term ended | Term ended May 2, 2025 | From the USPTO record |
| US 7,255,868 | Chimeric immunomodulatory compounds and methods of using the same—I Term ended Term ended Jun 2, 2024 · From the USPTO record | Term ended | Term ended Jun 2, 2024 | From the USPTO record |
| US 9,333,254 | Long term disease modification using immunostimulatory oligonucleotides Lapsed on the fee record Ended May 10, 2024 · From the USPTO record | Lapsed on the fee record | Ended May 10, 2024 | From the USPTO record |
| US 8,114,418 | Chimeric immunomodulatory compounds and methods of using the same—IV Term ended Term ended Feb 20, 2024 · From the USPTO record | Term ended | Term ended Feb 20, 2024 | From the USPTO record |
| US 8,222,398 | Chimeric immunomodulatory compounds and methods of using the same-II Term ended Term ended Jan 16, 2024 · From the USPTO record | Term ended | Term ended Jan 16, 2024 | From the USPTO record |
| US 8,158,768 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Formerly held Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |
| US 8,871,732 | Immunostimulatory Sequence Oligonucleotides and Methods of Using the Same Formerly held Term ended Term ended Dec 18, 2023 · Medium confidence | Term ended | Term ended Dec 18, 2023 | Medium confidence |